# Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

> **NCT07644052** · PHASE3 · RECRUITING · sponsor: **PleoPharma, Inc.** · enrollment: 420 (estimated)

## Conditions studied

- Cannabis Withdrawal

## Interventions

- **COMBINATION_PRODUCT:** PP-01
- **DRUG:** Nabilone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07644052
- **Lead sponsor:** PleoPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-17
- **Primary completion:** 2027-06
- **Final completion:** 2027-09
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644052, "Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*